SCHEMBL1319480

SCHEMBL1319480

CC(C)(C)CC(=O)Nc1nc2ccc(F)cn2c1-c1ccc(Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 4/20 0.43
KCNQ2 O43526 4/20 0.43
GPR139 Q6DWJ6 2/20 0.40
GABRD O14764 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRA4 P48169 1/20 0.40
GABRA1 P14867 2/20 0.38
GABRB2 P47870 2/20 0.38
SLC2A1 P11166 1/20 0.38
USP7 Q93009 1/20 0.37
CNR1 P21554 1/20 0.37
CSNK1D P48730 1/20 0.36
CSNK1E P49674 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
MAP3K5 Q99683 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1320161 0.94 KCNQ3 (0.45) KCNQ3KCNQ2USP7CSNK1DCSNK1E
SCHEMBL1321730 0.93 KCNQ3 (0.48) KCNQ3KCNQ2GABRA1GABRB2USP7
SCHEMBL1321283 0.90 GABRA1 (0.46) KCNQ3KCNQ2GPR139GABRA1GABRB2
SCHEMBL1321698 0.89 KCNQ3 (0.44) KCNQ3KCNQ2GABRA1GABRB2USP7
SCHEMBL1318630 0.88 KCNQ3 (0.43) KCNQ3KCNQ2GABRA1GABRB2USP7
SCHEMBL1321313 0.88 KCNQ3 (0.48) KCNQ3KCNQ2GPR139GABRA1GABRB2
SCHEMBL1318981 0.88 KCNQ3 (0.44) KCNQ3KCNQ2GPR139GABRA1GABRB2
SCHEMBL1320507 0.88 KCNQ3 (0.41) KCNQ3KCNQ2GPR139GABRDGABRB1
SCHEMBL1321569 0.87 KCNQ2 (0.45) KCNQ3KCNQ2GPR139GABRA1GABRB2
SCHEMBL1319203 0.87 KCNQ2 (0.41) KCNQ3KCNQ2GPR139GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018208-B2 Heterocycles as potassium channel modulators ICAGEN INC. (US) 2015-04-28 US disclosed
US-20130143889-A1 Heterocycles As Potassium Channel Modulators ICAGEN INC. (US) 2013-06-06 US disclosed
US-8431608-B2 Heterocycles as potassium channel modulators ICAGEN INC. (US) 2013-04-30 US disclosed
EP-2536718-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS Icagen, Inc. (US) 2012-12-26 EP disclosed
US-8058274-B2 Heterocycles as potassium channel modulators ICAGEN, INC. (US) 2011-11-15 US disclosed
WO-2011102964-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2011-08-25 WO disclosed
US-20100240663-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-09-23 US disclosed
EP-2178373-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS Icagen, Inc. (US) 2010-04-28 EP disclosed
US-20090062290-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2009-03-05 US disclosed
WO-2009026254-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143889-A1 Heterocycles As Potassium Channel Modulators KCNK10, KCNK9, KCNJ2 KCNQ3 29/4885KCNQ2 7/4885GPR139 965/4885
US-20090062290-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK2, KCNK17 KCNQ3 23/4885KCNQ2 7/4885GPR139 1384/4885
US-20100240663-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK2, KCNK17 KCNQ3 23/4885KCNQ2 7/4885GPR139 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.